OpGen, Inc., a Gaithersburg, Md.-based commercial stage whole-genome analysis company, has agreed to receive up to $17m in a new growth capital financing.
Backers include new and existing investors: Harris & Harris Group, Inc. and Cross Creek Capital joined Highland Capital Partners, Versant Ventures, jVen Capital and CHL Medical Partners.
In conjunction with the funding, Misti Ushio, Ph.D., of Harris & Harris Group, will join OpGen’s board of directors.
The company intends to use the funding to accelerate the commercialization of its Argus®Whole Genome Mapping System as well as its Genome-Builder™ tool suite for large genome sequencing assembly and data analysis and introduce a new application for whole human chromosome mapping, which could enable the discovery of a wide spectrum of structural variations to pinpoint the origins of genetic diseases.
Led by CEO Douglas White, OpGen develops accurate genomic and DNA analysis systems and services. Its Argus® Whole Genome Mapping System, GenomeBuilder™ and MapIt® Services provide high resolution, whole genome maps for sequence assembly and finishing, strain typing and comparative genomics in the life sciences market.
Customers include leading genomic research centers, biodefense organizations, academic institutions, clinical research organizations and biotechnology companies.
OpGen is currently hiring (http://www.opgen.com/company/careers)